U.S. Markets closed

AbbVie Inc. (ABBV)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
66.32+0.39 (+0.59%)
At close: 4:01PM EDT

66.32 0.00 (0.00%)
After hours: 6:03PM EDT

People also watch
ABTGILDCELGBMYBIIB

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064
United States
847-932-7900
http://www.abbvie.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees29,000

Key Executives

NameTitlePayExercisedAge
Mr. Richard A. GonzalezChairman and Chief Exec. Officer6.06M7.99M63
Mr. William J. ChaseChief Financial Officer and Exec. VP2.77M210.51k49
Mr. Michael E. Severino M.D.Chief Scientific Officer and Exec. VP of R&D2.66MN/A51
Ms. Laura J. SchumacherExec. VP of External Affairs, Gen. Counsel and Corp. Sec.3M6.03M54
Mr. Henry O. GosebruchChief Strategy Officer and Exec. VP3.37MN/A44
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; and M2Gen. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Corporate Governance

AbbVie Inc.’s ISS Governance QualityScore as of May 1, 2017 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.